Pages that link to "Q34310201"
Jump to navigation
Jump to search
The following pages link to MGMT: its role in cancer aetiology and cancer therapeutics (Q34310201):
Displaying 50 items.
- Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference (Q21261312) (← links)
- O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients (Q24607903) (← links)
- Epigenetics as a mechanism driving polygenic clinical drug resistance (Q24651640) (← links)
- Epigenetic treatment of solid tumours: a review of clinical trials (Q26773803) (← links)
- Targeting Aggressive Cancer Stem Cells in Glioblastoma (Q26799983) (← links)
- O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems (Q26853112) (← links)
- Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT (Q26862363) (← links)
- MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. (Q27851529) (← links)
- Predictive value of CHFR and MLH1 methylation in human gastric cancer (Q27852998) (← links)
- Mass spectrometry for the assessment of the occurrence and biological consequences of DNA adducts (Q28082391) (← links)
- Epigenome-based personalized medicine in human cancer (Q28083951) (← links)
- Molecular heterogeneity in glioblastoma: potential clinical implications (Q28088605) (← links)
- MiR-221/222 target the DNA methyltransferase MGMT in glioma cells (Q28118866) (← links)
- Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities (Q28285134) (← links)
- Fluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug Response (Q28551141) (← links)
- Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma (Q28731328) (← links)
- The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma (Q28741768) (← links)
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Q29547224) (← links)
- DNA repair modulates the vulnerability of the developing brain to alkylating agents (Q30488029) (← links)
- A distinct epigenetic signature at targets of a leukemia protein (Q33271210) (← links)
- Predictive and prognostic markers in neuro-oncology (Q33311133) (← links)
- Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). (Q33370672) (← links)
- Temozolomide: a milestone in neuro-oncology and beyond? (Q33372340) (← links)
- Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status (Q33382176) (← links)
- Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours (Q33396508) (← links)
- Current data and strategy in glioblastoma multiforme (Q33527073) (← links)
- Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas (Q33591900) (← links)
- Molecularly evolved thymidylate synthase inhibits 5-fluorodeoxyuridine toxicity in human hematopoietic cells (Q33691845) (← links)
- O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction (Q33804528) (← links)
- PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. (Q33958963) (← links)
- Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas (Q33973844) (← links)
- Integrating Epigenomics into Pharmacogenomic Studies (Q33980155) (← links)
- One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. (Q34003616) (← links)
- Targeting DNA repair pathways for cancer treatment: what's new? (Q34015040) (← links)
- A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects (Q34088805) (← links)
- Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region (Q34168829) (← links)
- Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells (Q34202863) (← links)
- Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. (Q34221722) (← links)
- Syntheses and characterizations of the in vivo replicative bypass and mutagenic properties of the minor-groove O2-alkylthymidine lesions (Q34249731) (← links)
- O6-Methylguanine DNA lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling network activation (Q34293997) (← links)
- DNA methyltransferases, DNA damage repair, and cancer (Q34298096) (← links)
- Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain (Q34400848) (← links)
- A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas (Q34427825) (← links)
- Alkylation sensitivity screens reveal a conserved cross-species functionome (Q34434871) (← links)
- Phosphorylated hMSH6: DNA mismatch versus DNA damage recognition (Q34441558) (← links)
- MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. (Q34507966) (← links)
- Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program (Q34571940) (← links)
- Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations (Q34625644) (← links)
- Role of MGMT as biomarker in colorectal cancer (Q34706115) (← links)
- Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival (Q34797919) (← links)